{"analyses":[{"ciNumSides":"TWO_SIDED","groupDescription":"Comparison between arms at Day 28 of treatment- HADS anxiety","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.945","statisticalMethod":"Wilcoxon (Mann-Whitney)","testedNonInferiority":false},{"ciNumSides":"TWO_SIDED","groupDescription":"Comparison between arms at Day 28 of treatment- HADS depression","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.316","statisticalMethod":"Wilcoxon (Mann-Whitney)","testedNonInferiority":false},{"ciNumSides":"TWO_SIDED","groupDescription":"Day 1 vs. Day 28 of treatment for the Placebo-First arm-HADS anxiety","groupIds":["OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.005","statisticalMethod":"t-test, 2 sided","testedNonInferiority":false},{"ciNumSides":"TWO_SIDED","groupDescription":"Day 1 vs. Day 28 of treatment for the Placebo-First arm-HADS depression","groupIds":["OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.005","statisticalMethod":"t-test, 2 sided","testedNonInferiority":false},{"ciNumSides":"TWO_SIDED","groupDescription":"Day 1 vs. Day 28 of treatment for the Armodafinil arm-HADS anxiety","groupIds":["OG000"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.001","statisticalMethod":"Wilcoxon (Mann-Whitney)","testedNonInferiority":false},{"ciNumSides":"TWO_SIDED","groupDescription":"Day 1 vs. Day 28 of treatment for the Placebo-First arm-HADS depression","groupIds":["OG000"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.315","statisticalMethod":"Wilcoxon (Mann-Whitney)","testedNonInferiority":false},{"ciNumSides":"TWO_SIDED","groupDescription":"Day 28 vs. Day 56 of treatment for the Armodafinil arm-HADS anxiety","groupIds":["OG000"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.933","statisticalMethod":"Wilcoxon (Mann-Whitney)","testedNonInferiority":false},{"ciNumSides":"TWO_SIDED","groupDescription":"Day 28 vs. Day 56 of treatment for the Armodafinil arm-HADS depression","groupIds":["OG000"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.378","statisticalMethod":"t-test, 2 sided","testedNonInferiority":false}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"21.4","value":"13.4"},{"groupId":"OG001","spread":"2.9","value":"8.3"}]}],"title":"Anxiety-Day 1 (n=18, 23)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.7","value":"7.8"},{"groupId":"OG001","spread":"3.2","value":"7.6"}]}],"title":"Depression-Day 1 (n=18, 23)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.6","value":"6.9"},{"groupId":"OG001","spread":"3.3","value":"5.5"}]}],"title":"Anxiety-Day 28 (n=19, 23)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.8","value":"10.3"},{"groupId":"OG001","spread":"3.6","value":"6.6"}]}],"title":"Depression-Day 28 (n=19, 23)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.4","value":"7.0"},{"comment":"Day 56 data was only evaluated for the Armodafinil arm","groupId":"OG001","spread":"NA","value":"NA"}]}],"title":"Anxiety-Day 56 (n=15)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.9","value":"5.7"},{"comment":"Day 56 data was only evaluated for the Armodafinil arm","groupId":"OG001","spread":"NA","value":"NA"}]}],"title":"Depression-Day 56 (n=15)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"25"}],"units":"Participants"}],"description":"Survey used to assess depression and anxiety. The test consists of 14 items (7 for anxiety and 7 for depression); there are 4 possible answers for each statement. Each item on the questionnaire is scored from 0-3 and this means that a person can score between 0 and 21 for either anxiety or depression. Higher scores= more anxiety or depression.","dispersionType":"Standard Error","groups":[{"description":"The patients receive armodafinil for all 56 days of the study.\n\nArmodafinil taken orally at 150 mg daily.","id":"OG000","title":"Armodafinil"},{"description":"These patients receive a placebo for the first 28 days of the study. They are then crossed over and receive armodafinil for the final 28 days of the study (days 29-56).\n\nPlacebo taken orally at 150 mg daily. Armodafinil taken orally at 150 mg daily.","id":"OG001","title":"Placebo-First"}],"paramType":"MEAN","reportingStatus":"POSTED","timeFrame":"Day 1, Day 28 and Day 56","title":"Hospital Anxiety and Depression Scale (HADS) Score","type":"SECONDARY","unitOfMeasure":"units on a scale"}